GNCAQ — Genocea Biosciences Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$12.49m
- $1.64m
Brief: Genocea Biosciences Q3 Loss Per Share $0.05
Genocea Biosciences Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Jennifer Herron, Of ADC Therapeutics, Joins Genocea Biosciences' Board Of Directors
Genocea Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Genocea Biosciences Inc expected to post a loss of 18 cents a share - Earnings Preview
Genocea Biosciences Inc expected to post a loss of 18 cents a share - Earnings Preview
Brief: Genocea Doses First Patient In Phase 1/2A Titan Clinical Trial For Gen-011 Neoantigen-Targeted T Cell Therapy
Brief: Genocea Presents Promising Long-Term Results From Gen-009 Neoantigen Vaccine Phase 1 Trial At Asco 2021
Genocea Biosciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Genocea Biosciences Inc - Qtrly Loss Per Share of $0.17
Brief: Genocea Reports Qtrly Loss Per Share $0.18
Brief: Genocea Sees Longer-Term Efficacy In Combination With Checkpoint Inhibitor For GEN-009 Neoantigen Vaccine In Q2
Brief: Genocea Presents Positive GEN-009 Clinical Results, Update On Gen-011 Program And New Inhibigentm Mechanism Of Action Data At SITC 2020
Brief: Genocea Biosciences Reports Q3 Loss Per Share $0.26
U.S. STOCKS ON THE MOVE-SolarEdge Technologies Inc, Snowflake Inc, Koppers Holdings Inc, Fulgent Genetics Inc
Genocea: Rises as FDA gives nod for start of cancer therapy study
Brief: Genocea Announces FDA Acceptance Of GEN-011 IND Application
Brief: Genocea Biosciences Files Stock Shelf Of Up To 21.2 Mln Shares Of Common Stock
Brief: Genocea To Present Positive Preliminary Clinical Data Evaluating Neoantigen Vaccine Gen-009 In Combination With Checkpoint Inhibitors